- Mar 20, 2017- TLE400 is a fixed-dose combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg -
- Mar 13, 2017
- Mar 10, 2017
- Mar 1, 2017Fourth Quarter Total Revenues Increase 31% and Full Year 2016 Total Revenues Increase 18%
- Feb 16, 2017U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for ReviewSecond Successful BLA Filing of the Partnership in the U.S.